
When 2-year-old goes into cardiac arrest, parents take life-saving action
It certainly wasn't on the Thomases' radar when their 2-year-old son went into sudden cardiac arrest in the middle of the night at their Illinois home.
When the child woke up screaming, his parents ran into the room.
"Hearing him scream out was alarming, as he usually slept soundly, and it was a horrible cry," Stephanie Thomas told Fox News Digital.
"When I went into his room, he continued to scream out and then face-plant into his crib."
At first, the Thomases thought their son was just having a night terror, so Stephanie — who is a clinical dietitian at OSF HealthCare Children's Hospital of Illinois — sat next to his crib with her hand on his back, trying to calm him down.
"When he finally settled, I could feel his breathing slowly come to a stop," she recalled. "I picked him up out of his crib and placed him on the floor. With him being unresponsive, I felt for a pulse and started CPR."
"I was petrified and confused about how my seemingly healthy 2-year-old was in this situation."
"I was petrified and confused about how my seemingly healthy 2-year-old was in this situation."
As Stephanie performed CPR, her husband, Kris, called 911.
Emergency responders rushed the boy to OSF HealthCare. After 11 days of testing, he was diagnosed with Brugada syndrome, a very rare heart condition that can cause sudden cardiac arrest and death.
Though there can be some signs of Brugada syndrome, such as fainting or passing out, the condition is often not discovered until cardiac arrest occurs.
The Thomases' son had a similar incident about a month before the cardiac arrest, which they now believe may have been his first episode.
"He woke up in the middle of the night with a horrible scream, had some gasping and was hard to calm," Stephanie recalled. "It was only a short period, and once he calmed, he seemed 'normal.' We assumed it was a night terror."
As Brugada syndrome is often inherited, the Thomases were both tested for genetic abnormalities, but it was determined that their son's syndrome is a "mosaic defect," which is when there are two or more genetically different sets of cells in the body.
The OSF team implanted the young boy with an EV-ICD (extravascular implantable cardioverter-defibrillator), which is positioned outside the heart's blood vessels. It is designed to detect and correct any abnormal heart rhythms.
This was the first time the device was implanted in a child at such a young age, the hospital noted in a press release.
Since the first episode, the Thomases' son has been hospitalized six more times. Each time an abnormal heart rhythm is detected, the EV-ICD delivers a "life-saving shock" to the boy's heart.
"Our son acts and appears healthy more than 99% of the time, until his heart gets into an arrhythmia that his body and medication cannot manage on their own," Stephanie told Fox News Digital. "In these cases, he receives a shock from his ICD."
The boy has been readmitted to the hospital due to arrhythmias and medication titration seven times since his initial discharge, his mother added.
Sunita Ferns, M.D., a pediatric electrophysiologist at OSF HealthCare Saint Francis Medical Center who is treating the Thomases' son, noted that her young patient is now "married to cardiology."
"We monitor these devices constantly. If we see any arrhythmia in the background, despite the medication he's on, we can offer him other technologies," Dr. Ferns said in the OSF press release.
"Ablative technologies can help modify the substrate, which is the tissue that's responsible for the bad rhythm."
To help control his arrhythmias, the boy also takes a compounded oral medication every six hours, which he will take for the rest of his life.
The parents said it can be challenging to navigate the episodes with a 2-year-old who can't understand what's happening.
"The hardest part is when he says things like, 'I can't use the elephant blankie because it shocked me,'" Stephanie said. "He makes these associations between being shocked and the objects or places around him."
There are specific triggers for the boy's arrhythmias, the Thomases have learned, such as low-grade fevers and even slight illnesses, like a cold.
"It is vital that we keep him as healthy as we can — which can be challenging with him being an active 2-year-old and having a 4-year-old," Stephanie said.
"We make sure that he stays up to date on his and our whole family's vaccines. We do our best to tightly regulate any temperatures."
"It is vital that we keep him as healthy as we can."
The Thomases now aim to raise awareness of the importance of having CPR training, being alert to warning signs and putting an emergency plan in place.
As a healthcare employee, Stephanie has maintained her Basic Life Support (BLS) certification for over 10 years.
For more Health articles, visit www.foxnews.com/health
"I have always said that I work with doctors and nurses, so felt that this was something I would never use — but the doctors and nurses were not in my house the night my son went into cardiac arrest, so it was left to me."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Associated Press
10 hours ago
- Associated Press
Hurricane Erin weakens to Category 3 as forecasters wait for northward turn
The Associated Press is an independent global news organization dedicated to factual reporting. Founded in 1846, AP today remains the most trusted source of fast, accurate, unbiased news in all formats and the essential provider of the technology and services vital to the news business. More than half the world's population sees AP journalism every day.
Yahoo
10 hours ago
- Yahoo
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool


Associated Press
11 hours ago
- Associated Press
Police and demonstrators clash in Valjevo as tensions soar in Serbia
The Associated Press is an independent global news organization dedicated to factual reporting. Founded in 1846, AP today remains the most trusted source of fast, accurate, unbiased news in all formats and the essential provider of the technology and services vital to the news business. More than half the world's population sees AP journalism every day.